Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their value in a single session. NEW YORK, June 2, 2026 /PRNewswire/ -- Abivax (NASDAQ: ABVX) shareholders more than to 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod.